CN114920746A - BTK (BTK inhibitory or degrading agent) and application thereof in medicine - Google Patents
BTK (BTK inhibitory or degrading agent) and application thereof in medicine Download PDFInfo
- Publication number
- CN114920746A CN114920746A CN202210485930.5A CN202210485930A CN114920746A CN 114920746 A CN114920746 A CN 114920746A CN 202210485930 A CN202210485930 A CN 202210485930A CN 114920746 A CN114920746 A CN 114920746A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- independently selected
- substituted
- ring
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 7
- 239000003795 chemical substances by application Substances 0.000 title description 3
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 230000000593 degrading effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 229940002612 prodrug Drugs 0.000 claims abstract description 25
- 239000000651 prodrug Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000013078 crystal Substances 0.000 claims abstract description 24
- 239000012453 solvate Substances 0.000 claims abstract description 22
- 239000002207 metabolite Substances 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- -1 C 2-6 Alkenyl radical Chemical class 0.000 claims description 193
- 125000000623 heterocyclic group Chemical group 0.000 claims description 58
- 229910052760 oxygen Inorganic materials 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 229910052731 fluorine Inorganic materials 0.000 claims description 46
- 125000001424 substituent group Chemical group 0.000 claims description 43
- 229910052794 bromium Inorganic materials 0.000 claims description 42
- 229910052801 chlorine Inorganic materials 0.000 claims description 42
- 229910052717 sulfur Inorganic materials 0.000 claims description 41
- 125000005842 heteroatom Chemical group 0.000 claims description 40
- 229910052740 iodine Inorganic materials 0.000 claims description 40
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000002837 carbocyclic group Chemical group 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 17
- 229910052805 deuterium Inorganic materials 0.000 claims description 17
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 15
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 125000002393 azetidinyl group Chemical group 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000004161 1,4-diazepinyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 abstract description 4
- 230000005496 eutectics Effects 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000000460 chlorine Substances 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 13
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 12
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- 125000003003 spiro group Chemical group 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- XWSWVRZFGHCELS-RPWUZVMVSA-N 1-[(3R,4S)-3-fluoro-1-[1-[(3-fluoroazetidin-3-yl)methyl]azetidin-3-yl]piperidin-4-yl]-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2[C@@H](CCN(C3)C4CN(CC5(CNC5)F)C4)[C@@H]3F)C2=NC=N1 XWSWVRZFGHCELS-RPWUZVMVSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 125000004452 carbocyclyl group Chemical group 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 238000001308 synthesis method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IBPCSNSCMQDWFI-PXJZQJOASA-N NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2[C@@H](CCN(C3)C4CN(CC(C5)(CN5C(C=C5)=CN=C5C(O)=O)F)C4)[C@@H]3F)C2=NC=N1 Chemical compound NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2[C@@H](CCN(C3)C4CN(CC(C5)(CN5C(C=C5)=CN=C5C(O)=O)F)C4)[C@@H]3F)C2=NC=N1 IBPCSNSCMQDWFI-PXJZQJOASA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001024304 Mino Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- UHEKCSFOMHTMSS-SXOMAYOGSA-N tert-butyl 3-[[3-[(3R,4S)-4-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-3-fluoropiperidin-1-yl]azetidin-1-yl]methyl]-3-fluoroazetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1(CN(C1)CC1N(CC[C@@H]1N(C2=NC=NC(N)=C22)N=C2C(C=C2)=CC=C2OC2=CC=CC=C2)C[C@H]1F)F)=O UHEKCSFOMHTMSS-SXOMAYOGSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229940081066 picolinic acid Drugs 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 108010026668 snake venom protein C activator Proteins 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 3
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- VLUPKMCHHSQPHP-OCARZQCDSA-N CC(C)(C)OC(N(C1)NC1(CN(C1)CC1N(CC[C@@H]1N(C2=NC=NC(N)=C22)N=C2C(C=C2)=CC=C2OC2=CC=CC=C2)C[C@H]1F)F)=O Chemical compound CC(C)(C)OC(N(C1)NC1(CN(C1)CC1N(CC[C@@H]1N(C2=NC=NC(N)=C22)N=C2C(C=C2)=CC=C2OC2=CC=CC=C2)C[C@H]1F)F)=O VLUPKMCHHSQPHP-OCARZQCDSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- CEEHTPKWXSQNKS-UHFFFAOYSA-N N1CC(C1)N1CC(C1)N1CCC(CC1)N1N=C(C=2C1=NC=NC=2N)C1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound N1CC(C1)N1CC(C1)N1CCC(CC1)N1N=C(C=2C1=NC=NC=2N)C1=CC=C(C=C1)OC1=CC=CC=C1 CEEHTPKWXSQNKS-UHFFFAOYSA-N 0.000 description 2
- JLLTWKCBRUKZQK-RTWAWAEBSA-N N1CC(C1)N1C[C@H]([C@H](CC1)N1N=C(C=2C1=NC=NC=2N)C1=CC=C(C=C1)OC1=CC=CC=C1)F Chemical compound N1CC(C1)N1C[C@H]([C@H](CC1)N1N=C(C=2C1=NC=NC=2N)C1=CC=C(C=C1)OC1=CC=CC=C1)F JLLTWKCBRUKZQK-RTWAWAEBSA-N 0.000 description 2
- FYYGTBKFPAGYCA-UHFFFAOYSA-N NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2C(CC3)CCN3C(C3)CN3C(C3)CN3C(C=C3)=CN=C3C(NC(CCC(N3)=O)C3=O)=O)C2=NC=N1 Chemical compound NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2C(CC3)CCN3C(C3)CN3C(C3)CN3C(C=C3)=CN=C3C(NC(CCC(N3)=O)C3=O)=O)C2=NC=N1 FYYGTBKFPAGYCA-UHFFFAOYSA-N 0.000 description 2
- JRQYZNYBPINAKR-CEMRBBIGSA-N NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2[C@@H](CCN(C3)C4CN(CC(C5)(CN5C(C=C5)=CN=C5C(NC(CCC(N5)=O)C5=O)=O)F)C4)[C@@H]3F)C2=NC=N1 Chemical compound NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2[C@@H](CCN(C3)C4CN(CC(C5)(CN5C(C=C5)=CN=C5C(NC(CCC(N5)=O)C5=O)=O)F)C4)[C@@H]3F)C2=NC=N1 JRQYZNYBPINAKR-CEMRBBIGSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- BZFDZFWLBXFTCF-UHFFFAOYSA-N O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C=O)C)=O)=O Chemical compound O=C1NC(CCC1N1C(N(C2=C1C=CC=C2C=O)C)=O)=O BZFDZFWLBXFTCF-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- KCMBKUFSDZMQEM-UHFFFAOYSA-N methyl 5-fluoropyridine-2-carboxylate Chemical compound COC(=O)C1=CC=C(F)C=N1 KCMBKUFSDZMQEM-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- PRBHEGAFLDMLAL-GQCTYLIASA-N (4e)-hexa-1,4-diene Chemical compound C\C=C\CC=C PRBHEGAFLDMLAL-GQCTYLIASA-N 0.000 description 1
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006044 1-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006045 2-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- QTFBPMJATBTHSY-UHFFFAOYSA-N 2h-furo[3,2-b]pyrrole Chemical group C1=NC2=CCOC2=C1 QTFBPMJATBTHSY-UHFFFAOYSA-N 0.000 description 1
- ASYONLUGMHMMDA-UHFFFAOYSA-N 2h-thieno[3,2-b]pyrrole Chemical group C1=NC2=CCSC2=C1 ASYONLUGMHMMDA-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- BSVYLJCOTFYPSN-UHFFFAOYSA-N 5h-furo[3,2-c]pyrazole Chemical group N1=NC2=CCOC2=C1 BSVYLJCOTFYPSN-UHFFFAOYSA-N 0.000 description 1
- RDHOEMPRFDWIHL-UHFFFAOYSA-N 5h-thieno[3,2-c]pyrazole Chemical group N1=NC2=CCSC2=C1 RDHOEMPRFDWIHL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
- UIQCPISYWCTVSP-UHFFFAOYSA-N CN(C(C(CN(C1)CC1N(C1)CC1N(CC1)CCC1N(C1=NC=NC(N)=C11)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=CC=C1)=C1N1C(CCC(N2)=O)C2=O)C1=O Chemical compound CN(C(C(CN(C1)CC1N(C1)CC1N(CC1)CCC1N(C1=NC=NC(N)=C11)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=CC=C1)=C1N1C(CCC(N2)=O)C2=O)C1=O UIQCPISYWCTVSP-UHFFFAOYSA-N 0.000 description 1
- MMIRZFMKNLVYPE-DGPALRBDSA-N COC(C(C=C1)=NC=C1N(C1)CC1(CN(C1)CC1N(CC[C@@H]1N(C2=NC=NC(N)=C22)N=C2C(C=C2)=CC=C2OC2=CC=CC=C2)C[C@H]1F)F)=O Chemical compound COC(C(C=C1)=NC=C1N(C1)CC1(CN(C1)CC1N(CC[C@@H]1N(C2=NC=NC(N)=C22)N=C2C(C=C2)=CC=C2OC2=CC=CC=C2)C[C@H]1F)F)=O MMIRZFMKNLVYPE-DGPALRBDSA-N 0.000 description 1
- LXJVNSIXVVBBOF-UHFFFAOYSA-N COC(C(C=C1)=NC=C1N(C1)CC1N(C1)CC1N(CC1)CCC1N(C1=NC=NC(N)=C11)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound COC(C(C=C1)=NC=C1N(C1)CC1N(C1)CC1N(CC1)CCC1N(C1=NC=NC(N)=C11)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O LXJVNSIXVVBBOF-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ABMOEUNAXOIGKC-UHFFFAOYSA-N NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2C(CC3)CCN3C(C3)CN3C(C3)CN3C(C=C3)=CN=C3C(O)=O)C2=NC=N1 Chemical compound NC1=C(C(C(C=C2)=CC=C2OC2=CC=CC=C2)=NN2C(CC3)CCN3C(C3)CN3C(C3)CN3C(C=C3)=CN=C3C(O)=O)C2=NC=N1 ABMOEUNAXOIGKC-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004599 benzpyrazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Chemical class 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N piperylene Natural products CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- VNAUDIIOSMNXBA-UHFFFAOYSA-N pyrazolo[4,3-c]pyrazole Chemical group N1=NC=C2N=NC=C21 VNAUDIIOSMNXBA-UHFFFAOYSA-N 0.000 description 1
- RQGPLDBZHMVWCH-UHFFFAOYSA-N pyrrolo[3,2-b]pyrrole Chemical group C1=NC2=CC=NC2=C1 RQGPLDBZHMVWCH-UHFFFAOYSA-N 0.000 description 1
- GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical group N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- ISYAISBXCKGQPD-UHFFFAOYSA-N tert-butyl 3-fluoro-3-formylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(C=O)C1 ISYAISBXCKGQPD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound shown in a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic crystal thereof, an intermediate and a preparation method thereof, and application in BTK related diseases such as tumors or autoimmune system diseases. B-L-K (I).
Description
Technical Field
The invention relates to a compound shown in a general formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic crystal thereof, an intermediate and a preparation method thereof, and application in BTK related diseases such as tumors or autoimmune system diseases.
Background
Bruton's Tyrosine Kinase (BTK) is a member of the non-receptor protein tyrosine kinase Tec family, is a key regulator in the B cell antigen receptor (BCR) signaling pathway, and is distributed in the lymphatic, hematopoietic, and blood systems. BTK mutations cause activation of signal pathways such as proliferation, differentiation and angiogenesis of downstream tumor cells, leading to X-linked agammaglobulinemia, non-hodgkin's lymphoma (NHL) and many B-cell malignancies, including Chronic Lymphocytic Leukemia (CLL), mantle cell lymphoma and diffuse large B-cell lymphoma. Because the BTK is mainly expressed in B cells and marrow cells, the BTK is a target with better targeting and safety.
PROTAC (protease targeting chimera) molecules are bifunctional compounds capable of simultaneously combining targeting proteins and E3 ubiquitin ligase, and the compounds can induce the recognition of the targeting proteins by proteasomes of cells, cause the degradation of the targeting proteins and effectively reduce the content of the targeting proteins in the cells. By introducing ligands capable of binding different target proteins into the ProTAC molecule, the application of the PROTAC technology to the treatment of various diseases becomes possible, and the technology has attracted much attention in recent years.
Disclosure of Invention
The invention develops a BTK inhibitor which has novel structure, good drug effect, high bioavailability and higher safety and is used for treating BTK related diseases such as tumors or autoimmune system diseases.
The invention develops a PROTAC compound of a BTK inhibitor and E3 ubiquitin ligase, which has novel structure, good drug effect, high bioavailability and higher safety and can inhibit or degrade BTK, and is used for treating BTK related diseases such as tumors or autoimmune system diseases.
As a first embodiment of the present invention, a compound represented by the following general formula (I) or a stereoisomer, tautomer, deuteron, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof,
B-L-K (I);
l is selected from-Ak 1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak 5-;
ak1, Ak2, Ak3, Ak4 and Ak5 are independently selected from CH 2 O or a bond;
cy1, Cy2, Cy3 and Cy4 are each independentlyA ring selected from 3 to 12 membered heterocycle, 3 to 12 membered cycloalkyl, 6 to 10 membered aryl or a bond, said heterocycle, cycloalkyl or aryl being optionally substituted with 1 to 4 groups selected from D, F, Cl, Br, I, OH, NH 2 、oxo、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S, N;
R b1 、R b2 Or R b3 Each independently selected from H, D, F, Cl, Br, I, OH, NH 2 、CN、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said alkyl and alkoxy being optionally substituted by 1 to 4 substituents selected from the group consisting of D, F, Cl, Br, I, OH, NH 2 、CN、CONH 2 、C 1-4 Alkyl or C 1-4 Substituted with a substituent of alkoxy;
n1 is selected from 0, 1,2, 3,4 or 5;
n2 is selected from 0, 1,2, 3 or 4;
n3 is selected from 0, 1 or 2;
Q is each independently selected from the group consisting of a bond, -O-, -S-, -CH 2 -、-NR q -、-CO-、-NR q CO-、-CONR q -or 3-12 membered heterocycle, said heterocycle optionally substituted with 1 to 4 substituents selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S or N;
R q is selected from H or C 1-6 An alkyl group;
each F is independently selected from C 3-20 Carbocyclic ring, C 6-20 An aromatic ring, a 3-20 membered heterocyclic ring, or a 5-20 membered heteroaromatic ring, the heterocyclic or heteroaromatic ring containing 1 to 4 heteroatoms selected from O, S or N;
R k2 each is independentIs selected from the group consisting of a bond, -C (═ O) -, -C (═ Se) -, -C (═ S) -, -P (═ O) H-, -P (═ O) (CH) 3 )-、-S(=O) 2 -, -S (═ O) -, or-C (R) k3 ) 2 -;
R k5 Is selected from C (R) k3 ) Or N;
R k1 or R k3 Each independently selected from H, D, F, Cl, Br, I, OH, O, NH 2 、CN、COOH、CONH 2 、C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 3-8 membered heterocyclyl, said alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl or heterocyclyl being optionally substituted with 1 to 4 substituents selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocyclyl containing 1 to 4 heteroatoms selected from O, S or N;
or two R k3 And together with the atom or ring skeleton to which they are directly attached form C 3-8 Carbocyclic or 3-8 membered heterocyclic ring, two R k1 And together with the atom or ring skeleton to which they are directly attached form C 3-8 A carbocycle or 3-8 membered heterocycle optionally substituted with 1 to 4 substituents selected from F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S or N;
R k4 each independently selected from H, D, OH, NH 2 、CN、CONH 2 、C 1-6 Alkyl radical, C 3-8 Cycloalkyl or 3-8 membered heterocyclyl, said alkyl, cycloalkyl or heterocyclyl being optionally substituted by 1 to 4 substituents selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocyclyl containing 1 to 4 heteroatoms selected from O, S or N;
p1 or p2 are each independently selected from 0, 1,2, 3,4 or 5.
As a second embodiment of the present invention, a compound represented by the aforementioned general formula (I) or a stereoisomer, a tautomer, a deuteron, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof,
l is selected from-Cy 1-, -Cy1-Cy2-, -Cy1-Cy2-Cy3-, -Cy1-Cy2-Cy3-Cy4-, -Cy1-Ak2-, -Cy1-Ak2-Cy2-, -Cy1-Cy2-Ak 3-or-Cy 1-Cy2-Ak3-Cy 3-;
ak2 and Ak3 are respectively and independently selected from CH 2 Or O;
cy1, Cy2 or Cy3 are each independently selected from one of the following substituted or unsubstituted groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, azacyclohexenyl, piperidinyl, morpholinyl, piperazinyl, 1, 4-diazepinyl, phenyl, cyclopropylaminocyclopropyl, cyclopropylbenzocyclobutyl, cyclopropylpentacyclopentyl, cyclopropylaminocyclohexyl, cyclobutylbenzocyclobutyl, cyclobutylpentacyclopentyl, cyclobutylocyclocyclohexyl, cyclopentocyclocyclopentyl, cyclopentocyclocyclohexyl, cyclohexylocyclohexyl, cyclopropylspirocyclopropyl, cyclopropylspirocyclobutyl spirobutyl, cyclopropylspirocyclopentyl, cyclopropylspirocyclohexyl, cyclobutyl spirocyclobutyl spirobutyl, cyclobutylspirocyclopentyl, cyclobutyl spirocyclohexyl, cyclopentspirocyclohexyl, cyclohexylspirocyclohexyl, cyclopropyloazetidinyl, cyclopropylpyrrolopyrrolidinyl, cyclopropylnopiperidinyl, cyclobutyloazetidinyl, cyclobutylobutylkinyl, cyclopentylpiperidyl, cyclohexylspirocyclohexyl, cyclopropyloxazetidiyl, cyclopropyloxazetidinyl, cyclobutyloxazetidinyl, cyclopentapyridyl, cyclopropyloxazetidinyl, cyclobutyloxazetidinyl, piperidinyl, and cyclopentadienylyl, Cyclobutyl-pyrrolopyrrolidinyl, cyclobutyl-oxopiperidinyl, cyclopentoazetidinyl, cyclopenteazolyl, cyclopenteaiperidyl, cyclohexyloazetidiyl, cyclohexyloxopyrrolidinyl, cyclohexyloxopiperidyl, azetidinoazetidinyl, azetidinobutylpyrrolidinyl, azetidinobiperidyl, pyrrolidinyloazetidiyl, pyrrolidinylopyrrolidinyl, pyrrolidinyloxopiperidyl, piperidinoazetidinyl, piperidinopyrrolidinyl, piperidinopiperidinyl, cyclobutyl spiroazacyclobutyl, cyclobutyl spiropyrrolidinyl, cyclobutyl spiropiperidinyl, cyclopentyl spiroazetidinyl, cyclopentyl spiropyrrolidinyl, cyclopentyl spiropiperidinyl, cyclohexyl spiroazetidinyl, cyclohexyl spiropyrrolidinyl, cyclohexyl spiropiperidinyl, azetidinyl spiroazetidinyl, azacyclyl.Butyl spiropyrrolidinyl, azetidinyl spiropiperidinyl, pyrrolidinylspiroazetidinyl, pyrrolidinyl spiropyrrolidinyl, pyrrolidinyl spiropiperidinyl, piperidinyl spiroazetidinyl, piperidinyl spiropyrrolidinyl, piperidinyl spiropiperidinyl, When substituted, is optionally substituted with 1 to 2 substituents selected from D, F, Cl, Br, I, OH, NH 2 、COOH、CN、=O、C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 Substituted by a substituent of alkoxy;
R b1 、R b2 Or R b3 Each independently selected from H, D, F, Cl, Br, I, OH, NH 2 、CN、CONH 2 Methyl, ethyl, methoxy and ethoxy, wherein the methyl, ethyl, methoxy and ethoxy are optionally substituted by 1 to 4 groups selected from D, F, Cl, Br, I, OH and NH 2 、CN、CONH 2 、C 1-4 Alkyl or C 1-4 Substituted by a substituent of alkoxy;
n1 or n2 are each independently selected from 0, 1,2 or 3;
the remaining definitions are the same as in the first embodiment of the present invention.
As a third embodiment of the present invention, a compound represented by the aforementioned general formula (I) or a stereoisomer, a tautomer, a deuteron, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof,
each Q is independently selected from the group consisting of a bond, -O-, -S-, -CH 2 -、-NH-、-CO-、-NHCO-、-CONH-;
Each F is independently selected from C 3-7 Monocyclic alkyl, C 5-10 And cycloalkyl group, C 5-12 Spiro cycloalkyl, C 5-10 Bridged cycloalkyl radical, C 4-7 Mono-heterocycloalkyl, C 5-10 And heterocyclic alkyl, C 5-12 Spiroheterocycloalkyl, C 5-10 Bridged heterocycloalkyl, C 6-14 Aryl, 5-10 membered heteroaryl, said heteroaryl or heterocycloalkyl containing 1 to 4 heteroatoms selected from O, S or N;
R k8 each independently selected from the group consisting of a bond,C(CH 3 ) 2 、CH 2 、-C(=O)-、-C(=Se)-、-C(=S)-、-P(=O)H-、-P(=O)(CH 3 )-、-S(=O) 2 -、-S(=O)-;
R k6 Each independently selected from S, O, CH 2 Or NH;
R k7 each independently selected from CH or N;
R k9 each independently selected from O, S, CH 2 CH, NH, or N;
p3 is selected from 1,2 or 3;
R k2 each independently selected from-C (═ O) -, -C (═ Se) -, -C (═ S) -, -P (═ O) H-, -P (═ O) (CH) 3 )-、-S(=O) 2 -, -S (═ O) -, or-CH 2 -;
R k5 Selected from CH or N;
R k1 、R k3 each independently selected from H, D, F, Cl, Br, I, OH, O, NH 2 、CF 3 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said alkyl or alkoxy being optionally substituted by 1 to 4 substituents selected from D, F, Cl, Br, I, OH or NH 2 Substituted with a substituent of (a);
or two R k3 And together with the atom or ring skeleton to which they are directly attached form C 3-6 Carbocyclic or 3-7 membered heterocyclic ring, two R k1 And together with the atom or ring skeleton to which they are directly attached form C 3-6 A carbocycle or 3-7 membered heterocycle, optionally substituted with 1 to 4 groups selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S or N;
R k4 each independently selected from H, D, OH, NH 2 、CF 3 CN or C 1-4 An alkyl group;
the remaining definitions are the same as in the first or second embodiment of the present invention.
As a fourth embodiment of the present invention, a compound represented by the aforementioned general formula (I) or a stereoisomer, a tautomer, a deuteron, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof,
each F is independently selected from Cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [1.1.1]Pentyl alkyl, bicyclo [2.2.2]Octyl, adamantyl, phenyl, naphthyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl,Imidazolyl, triazolyl, oxazolyl, furyl, thienyl, thiazolyl, 2-pyridone, benzoxazolyl, pyridoimidazolyl, benzimidazolyl, benzpyrazolyl, benzothiazolyl, benzothienyl, benzofuryl, benzopyrolyl, benzopyridyl, benzopyrazinyl, benzopyrimidinyl, benzopyrazinyl, benzotriazinyl, pyrrolopyrrolyl, pyrrolopyridyl, pyrrolopyrimidyl, pyrrolopyridazinyl, pyrrolopyrazinyl, imidazopyrimidinyl, imidazopyridyl, imidazopyrazinyl, imidazopyridyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, pyrimidopyridinyl, pyridopyridinyl, pyridopyrazinyl, pyridopyridazinyl, pyridazinopyridazinyl, pyrimidopyridazinyl, pyridopyrimidinyl, pyridinopyridyl, pyridopyridazinyl, pyridazinopyridazinyl, Pyridazinopyrazinyl, pyrazinopyrazinyl;
each Q is independently selected from a bond or-CH 2 -;
R k2 Each independently selected from-C (═ O) -, -C (═ Se) -, -C (═ S) -, -P (═ O) H-, -P (═ O) (CH) 3 )-;
R k1 、R k3 Each independently selected from H, D, F, Cl, Br, I, OH, O, NH 2 、CF 3 、CN、COOH、CONH 2 Methyl, ethyl, methoxy, ethoxy, said methyl, ethyl, methoxy, ethoxy optionally being substituted by 1 to 4 groups selected from D, F, Cl, Br, I, OH or NH 2 Substituted with the substituent(s);
or two R k1 And the atoms or the ring skeleton to which they are directly attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl group, optionally substituted by 1 to 4 groups selected from D, F, Cl, Br, I, OH or NH 2 Substituted with the substituent(s);
R k4 each independently selected from H or methyl;
the remaining definitions are the same as in the first, second or third embodiment of the present invention.
As a fifth embodiment of the present invention, a compound represented by the aforementioned general formula (I) or a stereoisomer, a tautomer, a deuteron, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a cocrystal thereof,
l is selected from-Cy 1-Cy2-Cy 3-or-Cy 1-Cy2-Ak3-Cy 3-;
ak3 is selected from CH 2 ;
Cy1, Cy2 or Cy3 are each independently selected from one of the following substituted or unsubstituted groups: when substituted, by 1 to 4 substituents selected from D, F, CF 3 OH, methyl, ═ O, hydroxymethyl, COOH, CN or NH 2 Substituted with the substituent(s);
the remaining definitions are the same as in the first, second, third or fourth embodiment of the present invention.
As a sixth embodiment of the present invention, a compound represented by the aforementioned general formula (I) or a stereoisomer, a tautomer, a deuteron, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a cocrystal thereof,
L is selected from one of the structural fragments shown in Table L-1;
TABLE L-1
K is selected from one of the structural fragments shown in Table K-1;
TABLE K-1
The invention relates to a compound or a stereoisomer, a tautomer, a deuteron, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic crystal thereof, wherein the compound is selected from one of structures shown in a table S-1:
TABLE S-1
The invention also provides a pharmaceutical composition, which comprises the compound or the stereoisomer, the tautomer, the deuteron, the solvate, the prodrug, the metabolite, the pharmaceutically acceptable salt or the eutectic crystal thereof, and a pharmaceutically acceptable carrier.
The invention also provides the use of a compound of any one of the above or a stereoisomer, a tautomer, a deuterode, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof for the manufacture of a medicament for the treatment of a disease associated with the inhibition or degradation of BTK kinase, selected from cancer.
The first synthesis method comprises the following steps:
the general formula (Z-1) and the general formula (Z-2) are subjected to reductive amination, nucleophilic substitution reaction or coupling reaction to obtain a corresponding general formula (Z-3), if an amino protecting group is arranged at the reaction position of the general formula (Z-3), the amino protecting group is removed firstly, then the amino protecting group and the general formula (Z-4) are subjected to nucleophilic substitution reaction to obtain a corresponding general formula (II), namely a general formula (I), and the preparation of a longer chain can be repeatedly carried out according to the above first step method and the preparation of the deaminating protecting group;
R 4 -Cy1-R 5 (Z-2-1)+R 6- Cy2-R 7 (Z-2-2)→R 4 -Cy1-Ak2-Cy2-R 7 (Z-2-3),
the reaction of the general formula (Z-2-1) with the general formula (Z-2-2) can be carried out by nucleophilic substitution reaction, coupling reaction or reductive amination to obtain the general formula (Z-2-3), and the preparation of longer chains can be repeatedly carried out according to the above method;
if the reaction position of (Z-2-1) has an amino protecting group, the reaction with the general formula (Z-2-2) after the protecting group is removed can obtain a general formula (Z-2-3) through nucleophilic substitution reaction or coupling reaction or reductive amination, and the preparation of a longer chain can be repeatedly prepared according to the method;
or the general formula (Z-1) and the general formula (Z-2-1) are subjected to nucleophilic substitution reaction, coupling reaction or reductive amination reaction (which can be obtained by increasing the length of the chain by the preparation method of the general formula (Z-2-3)) to obtain the corresponding general formula (II), namely the general formula (I), wherein the length of the L chain can be prepared by the preparation method of the general formula (Z-2-3).
And a second synthesis method comprises the following steps:
if the reaction site of the general formula (Z-2) has an amino protecting group, removing the amino protecting group, and then carrying out nucleophilic substitution reaction or coupling reaction with the general formula (Z-4) to obtain a corresponding general formula (Z-5), and carrying out nucleophilic substitution reaction or coupling reaction on the general formula (Z-5) and the general formula (Z-1) to obtain a corresponding general formula (II), namely a general formula (I);
the third synthesis method comprises the following steps:
part of the chain L can firstly carry out nucleophilic substitution reaction or coupling reaction on the general formula (Z-1), then carries out nucleophilic substitution reaction or coupling reaction on the chain L and other parts of the chain L (the synthetic method is shown in the general formula (Z-2-3) for preparation), and so on until the general formula (Z-3) is obtained, and the general formula (Z-3) and the general formula (Z-4) obtain the corresponding general formula (II), namely the general formula (I) through the nucleophilic substitution reaction or coupling reaction;
the synthesis method comprises the following steps:
or part of the chain L can be subjected to nucleophilic substitution reaction or coupling reaction before the general formula (Z-4), and then subjected to nucleophilic substitution reaction or coupling reaction with other parts of the chain L (the synthetic method is shown in the general formula (Z-2-3) for preparation), and so on until the general formula (Z-5) is obtained, and the general formula (Z-5) and the general formula (Z-1) are subjected to nucleophilic substitution reaction or coupling reaction to obtain the corresponding general formula (II), namely the general formula (I).
Unless stated to the contrary, the terms used in the specification and claims of this application have the following meanings.
The carbon, hydrogen, oxygen, sulfur and nitrogen or F, Cl, Br and I related in the groups and compounds of the invention all comprise the same positionOptionally, the carbon, hydrogen, oxygen, sulfur or nitrogen referred to in the groups and compounds of the invention are further replaced by one or more isotopes of their corresponding carbon, wherein isotopes of carbon include 12 C、 13 C and 14 c, isotopes of hydrogen including protium (H), deuterium (D, also called deuterium), tritium (T, also called deuterium), isotopes of oxygen including 16 O、 17 O and 18 isotopes of O, S including 32 S、 33 S、 34 S and 36 isotopes of S, nitrogen include 14 N and 15 isotopes of N, F include 17 F and 19 isotopes of F, chlorine including 35 Cl and 37 cl, isotopes of bromine including 79 Br and 81 Br。
"halogen" means F, Cl, Br or I.
"halo-substituted" means F, Cl, Br or I-substituted, including but not limited to 1 to 10 substituents selected from F, Cl, Br or I, 1 to 6 substituents selected from F, Cl, Br or I, 1 to 4 substituents selected from F, Cl, Br or I. "halogen-substituted" is simply referred to as "halo".
"alkyl" refers to a substituted or unsubstituted straight or branched chain saturated aliphatic hydrocarbon group, including, but not limited to, alkyl of 1 to 20 carbon atoms, alkyl of 1 to 8 carbon atoms, alkyl of 1 to 6 carbon atoms, alkyl of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neo-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; alkyl groups, as found herein, are defined consistent with this definition. The alkyl group may be monovalent, divalent, trivalent or tetravalent.
"heteroalkyl" means that 1 or more (including but not limited to 2,3, 4, 5, or 6) carbon atoms in a substituted or unsubstituted alkyl group are replaced with a heteroatom (including but not limited to N, O or S). Non-limiting examples include-X (CH) 2 )v-X(CH 2 )v-X(CH 2 ) v-H (v is an integer from 1 to 5, X is each independently selected from a bond or a heteroatom including but not limited to N, O or S, and has at least 1X is selected from a heteroatom, and N or S in the heteroatom may be oxidized to various oxidation states). The heteroalkyl group may be monovalent, divalent, trivalent, or tetravalent.
"alkylene" refers to a substituted or unsubstituted, straight and branched chain, divalent saturated hydrocarbon radical, including- (CH) 2 ) v - (v is an integer of 1 to 10), examples of the alkylene group include, but are not limited to, methylene, ethylene, propylene, butylene, and the like.
"Heteroalkylidene" means a substituted or unsubstituted alkylene group in which 1 or more (including but not limited to 2,3, 4, 5, or 6) carbon atoms are replaced with a heteroatom (including but not limited to N, O or S). Non-limiting examples include-X (CH) 2 )v-X(CH 2 )v-X(CH 2 ) v-, v is an integer from 1 to 5, each X is independently selected from the group consisting of a bond, N, O or S, and at least 1X is selected from the group consisting of N, O or S.
"cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon group, typically having from 3 to 10 carbon atoms, non-limiting examples including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, and the like. Cycloalkyl groups, as found herein, are defined as above. The cycloalkyl group may be monovalent, divalent, trivalent or tetravalent.
"heterocycloalkyl" refers to a substituted or unsubstituted saturated heteroatom-containing cyclic hydrocarbon group, including but not limited to 3 to 10 atoms, 3 to 8 atoms, containing 1 to 3 heteroatoms selected from N, O or S, optionally substituted N, S in the ring of the heterocycloalkyl can be oxidized to various oxidation states. Heterocycloalkyl may be attached to a heteroatom or carbon atom, heterocycloalkyl may be attached to an aromatic ring or to a non-aromatic ring, heterocycloalkyl may be attached to a bridged or spiro ring, non-limiting examples include oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydro-2H-pyranyl, dioxolanyl, dioxanyl, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl. The heterocycloalkyl radical may be monovalent, divalent, trivalent or tetravalent
"alkenyl" means a substituted or unsubstituted straight and branched chain unsaturated hydrocarbon group having at least 1, and typically 1,2 or 3 carbon double bonds, the backbone including, but not limited to, 2 to 10, 2 to 6 or 2 to 4 carbon atoms, examples of alkenyl include, but are not limited to, vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1, 3-butadiene, 1, 3-pentadiene, 1, 4-hexadiene, and the like; alkenyl groups are present herein, the definition of which is consistent with the present definition. The alkenyl group may be monovalent, divalent, trivalent or tetravalent.
"alkynyl" means a substituted or unsubstituted, straight and branched, monovalent, unsaturated hydrocarbon radical having at least 1, and typically 1,2 or 3 carbon-carbon triple bonds, the backbone containing from 2 to 10 carbon atoms, including but not limited to from 2 to 6 carbon atoms in the backbone and from 2 to 4 carbon atoms in the backbone, examples of alkynyl include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, 4-decynyl and the like; alkynyl groups can be monovalent, divalent, trivalent or tetravalent.
"alkoxy" means a substituted or unsubstituted-O-alkyl group. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropoxy, and cyclobutoxy.
"carbocyclyl" or "carbocycle" means substituted or unsubstitutedSubstituted saturated or unsaturated aromatic or non-aromatic rings which may be 3 to 8 membered monocyclic, 4 to 12 membered bicyclic or 10 to 15 membered tricyclic ring systems, the carbocyclic group may be attached to an aromatic or non-aromatic ring, which is optionally monocyclic, bridged or spiro. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, benzene ring, naphthalene ring, and mixtures thereof,"carbocyclyl" or "carbocycle" may be monovalent, divalent, trivalent, or tetravalent.
"heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring which may be a 3-to 8-membered monocyclic, 4-to 12-membered bicyclic, or 10-to 15-membered tricyclic ring system and contain 1 or more (including but not limited to 2,3, 4, or 5) heteroatoms selected from N, O or S, optionally substituted N, S of the heterocyclyl ring being oxidizable to various oxidation states. The heterocyclic group may be attached to a heteroatom or carbon atom, the heterocyclic group may be attached to an aromatic ring or a non-aromatic ring, the heterocyclic group may be attached to a bridged or spiro ring, non-limiting examples of which include oxiranyl, aziridinyl, oxetanyl, azetidinyl, 1, 3-dioxolanyl, 1, 4-dioxolanyl, 1, 3-dioxanyl, azepinyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1, 3-dithiayl, dihydrofuranyl, dihydropyranyl, dithiapentyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridyl, pyrrolopyridyl, dihydropyranyl, spirocyclo-pyridyl, spiro-pyridyl, spirocyclo-pyridyl, oxacycloheptyl, azanyl, pyridyl, oxathianyl, thianyl, thienyl, pyridyl, etc, Benzodihydrofuranyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothienyl, benzofuranyl, benzopyrolyl, benzimidazolyl, benzothienylAzolyl, benzoxazolyl, benzopyridyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo [3.2.1]Octyl, azabicyclo [5.2.0 ] s]Nonoalkyl oxatricyclo [5.3.1.1 ]]Dodecyl, azaadamantyl, oxaspiro [3.3 ]]A heptalkyl group, "Heterocyclyl" or "heterocycle" may be monovalent, divalent, trivalent or tetravalent.
"spiro" or "spirocyclic" refers to a polycyclic group that shares a single atom (referred to as a spiro atom) between substituted or unsubstituted monocyclic rings, the number of ring atoms in the spiro system including, but not limited to, 5 to 20, 6 to 14, 6 to 12, 6 to 10, wherein one or more of the rings may contain 0 or more (including but not limited to 1,2, 3 or 4) double bonds, and optionally may contain 0 to 5 rings selected from N, O or S (═ O) n A heteroatom of (a).
"fused ring" or "fused ring group" refers to a polycyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, wherein one or more rings may contain 0 or more (including but not limited to 1,2, 3, or 4) double bonds, and may be substituted or unsubstituted, and each ring in the fused ring system may contain 0 to 5 heteroatoms or heteroatom-containing groups (including but not limited to those selected from N, S (═ O) n Or O, n is 0, 1 or 2). The number of ring atoms in the fused ring system includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, 5 to 10. Non-limiting examples include: the "fused ring" or "fused ring group" may be monovalent, divalent, trivalent or tetravalent.
"bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing any two atoms not directly attached, which may contain 0 or more double bonds, and any ring in the ring system may contain 0 to 5 heteroatoms selected or heteroatom containing groups (including but not limited to N, S (═ O) n or O, where n is 0, 1, 2). The number of ring atoms includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, or 5 to 10. Non-limiting examples include Cubane and adamantane. The "bridge ring" or "bridge ring group" may be monovalent, divalent, trivalent, or tetravalent.
"carbocyclyl", "spirocarbocyclyl" or "carbospirocyclic" refers to a "spiro" ring whose ring system consists of only carbon atoms. The "carbospiro", "spirocyclic carbocyclyl", "spirocarbocyclyl" or "carbospiro" group, as referred to herein, is defined in accordance with the definition of spiro.
"carbocyclic", "fused carbocyclic group" or "fused carbocyclic group" means that the ring system is "fused" consisting of only carbon atoms. "carbocyclic ring", "fused carbocyclic ring group", "fused carbocyclic group", or "fused carbocyclic group" as used herein, is defined in accordance with fused rings.
"Carbobridged ring", "bridged carbocyclyl" or "carbocyclyl" refer to a "bridged ring" in which the ring system consists of only carbon atoms. "Carbobridged ring", "bridged carbocyclyl", or "carbobridyclyl" as used herein, is defined in accordance with the definition of bridged ring.
"Heteromonocyclic", "monocyclic heterocyclyl" or "heteromonocyclic" refers to "heterocyclyl" or "heterocycle" of a monocyclic ring system, and heterocyclyl, "monocyclic heterocyclyl" or "heteromonocyclic" as found herein, is defined consistent with the definition of heterocycle.
"Heterocyclo", "heterocyclocyclyl" or "heterocyclocyclyl" means a "fused ring" containing heteroatoms. The term "fused ring" as used herein refers to a "fused ring," fused ring group, "fused heterocyclic group," or "fused ring group," which is defined as being fused.
"Heterospirocyclic", "heterospirocyclic", "spiroheterocyclic" or "heterospirocyclic" refers to "spirocyclic" containing heteroatoms. The definition of heterospiro, "heterospiro ring", "spiro heterocyclic" or "heterospiro ring" as used herein is consistent with spiro rings.
"heterobridged ring," "heterobridged ring group," "bridged heterocyclic group," or "heterobridged ring group" refers to a "bridged ring" containing a heteroatom. The term "heterobridged ring", "heterobridged ring group", "bridged heterocyclic group" or "heterobridged ring group", as used herein, is defined in accordance with the bridged ring.
"aryl" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single or fused ring, the number of ring atoms in the aromatic ring including, but not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring in which the ring to which the parent structure is attached is an aryl ring, non-limiting examples of which include a phenyl ring, a naphthyl ring,The "aryl" or "aromatic ring" may be monovalent, divalent, trivalent, or tetravalent. When divalent, trivalent, or tetravalent, the attachment site is located on the aryl ring.
"heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group and contains from 1 to 5 selected heteroatoms or heteroatom-containing groups (including but not limited to N, O or S (═ O) n, n is 0, 1, 2), and the number of ring atoms in the heteroaromatic ring includes but is not limited to 5 to 15, 5 to 10, or 5 to 6. Non-limiting examples of heteroaryl groups include, but are not limited to, pyridinePhenyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazolyl, benzimidazole, benzopyridine, pyrrolopyridine, and the like. The heteroaryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring in which the ring to which the parent structure is attached is a heteroaryl ring, non-limiting examples of which includeHeteroaryl groups, as found herein, are defined in accordance with the present definition. Heteroaryl groups may be monovalent, divalent, trivalent, or tetravalent. When divalent, trivalent, or tetravalent, the attachment site is on the heteroaryl ring.
The "5-membered and 5-membered heteroaromatic ring" means a 5-and 5-membered fused heteroaromatic ring in which at least 1 ring of 2 fused rings contains 1 or more heteroatoms (including but not limited to O, S or N), and the whole group has aromaticity, and non-limiting examples include pyrrolopyrrole rings, pyrazolopyrrole rings, pyrazolopyrazole rings, pyrrolofuran rings, pyrazolofuran rings, pyrrolothiophene rings, pyrazolothiophene rings.
"5 and 6 membered heteroaromatic ring" means a 5 and 6 membered fused heteroaromatic ring wherein at least 1 ring of the 2 fused rings contains more than 1 heteroatom (including but not limited to O, S or N) and the entire group is aromatic, non-limiting examples include benzo 5 membered heteroaryl, 6 membered heteroaromatic ring and 5 membered heteroaromatic ring.
"substituted" or "substituted" means substituted with 1 or more (including but not limited to 2,3, 4, or 5) substituents including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro ring, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid, formate, - (CH) 2 ) m -C(=O)-R a 、-O-(CH 2 ) m -C(=O)-R a 、-(CH 2 ) m -C(=O)-NR b R c 、-(CH 2 ) m S(=O) n R a 、-(CH 2 ) m -alkenyl-R a 、OR d Or- (CH) 2 ) m -alkynyl-R a (wherein m, n are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NR b R c Etc. wherein R is b And R c Independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, R b And R c Five or six membered cycloalkyl or heterocyclyl groups may be formed. R a And R d Each independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
By "containing 1 to 5 heteroatoms selected from O, S, N" is meant containing 1,2, 3,4 or 5 heteroatoms selected from O, S, N.
"substituted with 0 to X substituents" means substituted with 0, 1,2, 3.. X substituents, X is selected from any integer between 1 and 10. By "substituted with 0 to 4 substituents" is meant substituted with 0, 1,2, 3, or 4 substituents. By "substituted with 0 to 5 substituents" is meant substituted with 0, 1,2, 3,4, or 5 substituents. If "the heterobridged ring is optionally further substituted with 0 to 4 substituents selected from H or F" means that the heterobridged ring is optionally further substituted with 0, 1,2, 3 or 4 substituents selected from H or F.
X-Y membered rings (X is selected from integers less than Y and greater than 3, and Y is selected from any integer between 4 and 12) include X +1, X +2, X +3, X +4. Rings include heterocyclic, carbocyclic, aromatic, aryl, heteroaryl, cycloalkyl, heteromonocyclic, heteroatomic, heterocyclic spiro, or heterobridged rings. For example, "4-7 membered heteromonocyclic" refers to a 4-, 5-, 6-, or 7-membered heteromonocyclic ring, and "5-10 membered heterobicyclic ring" refers to a 5-, 6-, 7-, 8-, 9-, or 10-membered heterobicyclic ring.
"optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs or does not. Such as: "alkyl optionally substituted with F" means that the alkyl group may, but need not, be substituted with F, and the description includes the case where the alkyl group is substituted with F and the case where the alkyl group is not substituted with F.
By "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" is meant a salt of a compound of the invention that retains the biological effectiveness and properties of the free acid or free base obtained by reaction with a non-toxic inorganic or organic base, and the free base obtained by reaction with a non-toxic inorganic or organic acid.
"pharmaceutical composition" refers to a mixture of one or more compounds described herein, or stereoisomers, tautomers, deuterons, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or co-crystals thereof, and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients, and/or one or more other therapeutic agents.
By "carrier" is meant a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
"excipient" refers to an inert substance added to a pharmaceutical composition to facilitate administration of a compound. Non-limiting examples include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, binders, and disintegrating agents.
By "prodrug" is meant a compound of the invention that is metabolically convertible in vivo to a biologically active compound. Prodrugs of the invention are prepared by modifying an amino or carboxyl group in a compound of the invention, which modification may be removed by routine manipulation or in vivo, to yield the parent compound. When a prodrug of the present invention is administered to a mammalian subject, the prodrug is cleaved to form a free amino or carboxyl group.
"cocrystal" refers to a crystal of an Active Pharmaceutical Ingredient (API) and a cocrystal former (CCF) bound by hydrogen bonding or other non-covalent bonds, wherein the API and CCF are both solid in their pure state at room temperature and a fixed stoichiometric ratio exists between the components. A co-crystal is a multi-component crystal that contains both a binary co-crystal formed between two neutral solids and a multicomponent co-crystal formed between a neutral solid and a salt or solvate.
"animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.
"stereoisomers" refers to isomers resulting from the different arrangement of atoms in a molecule, including cis, trans isomers, enantiomers and conformational isomers.
"tautomer" refers to functional group isomers resulting from rapid movement of an atom in two positions in a molecule, such as keto-enol isomers and amide-imino-enol isomers, and the like.
“IC 50 "is the concentration of drug or inhibitor required to inhibit half of a given biological process (or some component of the process such as an enzyme, receptor, cell, etc.).
Detailed Description
The following examples illustrate the technical solutions of the present invention in detail, but the scope of the present invention includes but is not limited thereto.
The structure of the compounds is determined by Nuclear Magnetic Resonance (NMR) or (and) Mass Spectrometry (MS). NMR shift (. delta.) at 10 -6 The units in (ppm) are given. NMR was measured using (Bruker Avance III 400 and Bruker Avance 300) nuclear magnetic spectrometers in deuterated dimethyl sulfoxide (DMSO-d) 6 ) Deuterated chloroform (CDCl) 3 ) Deuterated methanol (CD) 3 OD), internal standard Tetramethylsilane (TMS);
MS was measured using Agilent 6120B (ESI) and Agilent 6120B (APCI);
HPLC was carried out using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18100X 4.6mm, 3.5. mu.M);
the thin layer chromatography silica gel plate is prepared from cigarette bench yellow sea HSGF 254 Or Qingdao GF 254 Silica gel plate with specification of 0.15-0.20 mm for Thin Layer Chromatography (TLC), and specification of 0.4-0.5 mm for thin layer chromatography separation and purification product;
the column chromatography generally uses 200-mesh and 300-mesh silica gel of the Tibet yellow sea silica gel as a carrier;
the known starting materials of the present invention can be synthesized by methods known in the art or can be purchased from companies such as Tatan technology, Annaiji chemistry, Shanghai Demer, Chengdong chemical industry, Shaoshanghi chemical technology, and Bailingwei technology;
P13I:(synthetic references: Y.Sun, X.ZHao, N.Ding, H.Gao, Y.Wu, Y.Yang, M.ZHao, J.Hwang, Y.Song, W.Liu, Y.Rao, Cell Res.2018,28,779-
Tf: a trifluoromethanesulfonyl group;
boc: a tert-butoxycarbonyl group;
ts: a p-toluenesulfonyl group;
cbz: a benzyloxycarbonyl group;
TMS: trimethylsilyl group.
Example 1
3- (4- ((3- (4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) piperidin-1-yl) - [1,3 '-diazetidine ] -1' -yl) methyl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) piperidine-2, 6-dione (Compound 1)
3-(4-((3-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-[1,3'-biazetidin]-1'-yl)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione
1- [1- [1- (azetidin-3-yl) azetidin-3-yl ] -4-piperidinyl ] -3- (4-phenoxyphenyl) pyrazolo [3,4-d ] pyrimidin-4-amine (1a) (synthesis see WO2020239103) (173mg,0.35mmol) was dissolved in 10mL of THF and 3mL of DMSO, 1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [ d ] imidazole-4-carbaldehyde (1b) (synthesis see WO2020113233) (50mg, 0.17mmol) was added, the reaction was adjusted to pH 6 with acetic acid, stirred at room temperature for 3H, sodium triacetoxyborohydride (92mg, 0.43mmol), stirred at room temperature for 16 h. Slowly adding 10mL of saturated aqueous sodium bicarbonate solution into the reaction system, extracting with 100mL of dichloromethane, washing the organic phase with 50mL of water, drying over anhydrous sodium sulfate, concentrating under reduced pressure, and separating and purifying the crude product by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 20:1) to obtain 3- (4- ((3- (4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) piperidin-1-yl) - [1,3 '-diazacyclobutan ] -1' -yl) methyl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) piperidin-2, 6-dione (Compound 1) (30mg, yield from Compound 1 b: 23%).
1 H NMR(400MHz,CDCl 3 )δ10.30–10.04(m,1H),8.42–8.30(m,1H),7.70–7.60(m,2H),7.45–7.35(m,2H),7.23–7.02(m,5H),7.00–6.90(m,2H),6.83–6.72(m,1H),5.81(br.s,2H),5.25–5.16(m,1H),4.86–4.71(m,1H),3.91–3.71(m,5H),3.70–3.54(m,2H),3.53–3.30(m,3H),3.28–3.04(m,5H),2.97–2.88(m,2H),2.88–2.79(m,2H),2.78–2.65(m,1H),2.45–2.35(m,2H),2.22–1.97(m,5H).
LCMS m/z=768.4[M+1] +
Example 2:
5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) -N- (2, 6-dioxopiperidin-3-yl) pyridinecarboxamide (Compound 2)
5-(3-((3-((3R,4S)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-fluoropiperidin-1-yl)azetidin-1-yl)methyl)-3-fluoroazetidin-1-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide
The first step is as follows: 3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazaazetidine-1-carboxylic acid tert-butyl ester (2b)
tert-butyl 3-((3-((3R,4S)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-fluoropiperidin-1-yl)azetidin-1-yl)methyl)-3-fluoroazetidine-1-carboxylate
1- ((3R,4S) -1- (azetidin-3-yl) -3-fluoropiperidin-4-yl) -3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-4-amine (2a) (synthesis method is disclosed in WO2020239103) (510mg,1.11mmol) is added to 50mL of 1, 2-dichloroethane, tert-butyl 3-fluoro-3-formylazetidine-1-carboxylate (synthesis method is disclosed in WO2018089355) (304mg, 1.5mmol) is added, after 1H reaction at room temperature, sodium triacetoxyborohydride (318mg,1.5mmol) is added, and the reaction is continued at room temperature for 12H. 50mL of methylene chloride was added to the reaction system, the pH was adjusted to 9.0 with a saturated sodium bicarbonate solution, the organic phase was separated, the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (methylene chloride/methanol (v/v) ═ 10:1) to give 3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazacyclobutan-1-carboxylic acid tert-butyl ester (2b) (600mg, yield: 84%).
LCMS m/z=647.5[M+1] + 。
The second step is that: 1- ((3R,4S) -3-fluoro-1- (1- ((3-fluoroazetidin-3-yl) methyl) azetidin-3-yl) -piperidin-4-yl) -3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-4-amine (2c)
1-((3R,4S)-3-fluoro-1-(1-((3-fluoroazetidin-3-yl)methyl)azetidin-3-yl)piperidin-4-yl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Tert-butyl 3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazazetidin-1-carboxylate (2b) (600mg, 0.93mmol) was dissolved in 20mL of methanol, and 20mL of 4 mol/L1, 4-dioxane hydrochloride solution was added and reacted at room temperature for 1H. The reaction solution was concentrated under reduced pressure, dissolved in 100mL of dichloromethane, adjusted to pH 12.0 with 3mol/L sodium hydroxide solution, the organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude 1- ((3R,4S) -3-fluoro-1- (1- ((3-fluoroazetidin-3-yl) methyl) azetidin-3-yl) -piperidin-4-yl) -3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-4-amine (2c) (450 mg).
LCMS m/z=547.3[M+1] + 。
The third step: methyl 5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) picolinate (2d)
methyl 5-(3-((3-((3R,4S)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-fluoropiperidin-1-yl)azetidin-1-yl)methyl)-3-fluoroazetidin-1-yl)picolinate
The crude 1- ((3R,4S) -3-fluoro-1- (1- ((3-fluoroazetidin-3-yl) methyl) azetidin-3-yl) -piperidin-4-yl) -3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-4-amine (2c) (500mg) described above was dissolved in 10mL of DMSO, 1.0mL of DIPEA and methyl 5-fluoropicolinate (200mg, 1.29mmol) were added, and the mixture was warmed to 95 ℃ for 7H. The reaction mixture was cooled to room temperature, 100mL of purified water was added to precipitate a solid, which was filtered, the filter cake was dissolved in a mixed solvent of dichloromethane/methanol (v/v) ═ 10:1, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give methyl 5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) picolinate (2d) (480mg, two-step yield from compound 2 b: 68%).
LCMS m/z=682.3[M+1] +
The fourth step: 5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) picolinic acid (2e)
5-(3-((3-((3R,4S)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-fluoropiperidin-1-yl)azetidin-1-yl)methyl)-3-fluoroazetidin-1-yl)picolinic acid
Methyl 5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) picolinate (2d) (480mg, 0.7mmol) was added to a mixed solvent of 10mL tetrahydrofuran, 10mL methanol and 10mL purified water, and sodium hydroxide solid (800mg,20mmol) was added and reacted at room temperature for 2H. The reaction solution was concentrated under reduced pressure, the pH of the system was adjusted to 6.0 with 1mol/L aqueous hydrochloric acid, 60mL of dichloromethane was added for extraction, the organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product of 5- (3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazaazetidin-1-yl) picolinic acid (2e) (350 mg).
The fifth step: 5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) -N- (2, 6-dioxopiperidin-3-yl) picolinamide (Compound 2)
5-(3-((3-((3R,4S)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-fluoropiperidin-1-yl)azetidin-1-yl)methyl)-3-fluoroazetidin-1-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide
To the crude 5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) picolinic acid (2e) (350mg) above was added 10mL of DMF, followed by 3-aminopiperidine-2, 6-dione hydrochloride (250mg, 1.5mmol) and 1.0mL of triethylamine, followed by HATU (300mg, 0.8mmol) and reacted at room temperature for 16H. To the reaction solution was added 100mL of purified water to precipitate a solid, which was filtered, the filter cake was dissolved in a mixed solvent of dichloromethane/methanol (v/v) ═ 10:1, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 10:1) to give 5- (3- ((3- ((3R,4S) -4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -3-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -3-fluoroazetidin-1-yl) -N- (2, 6-dioxopiperidin-3-yl) pyridinecarboxamide (compound 2) (180mg, the two-step overall yield was calculated from compound 2 d: 33%).
1 H NMR(400MHz,CDCl 3 )δ8.69(br.s,1H),8.41(d,1H),8.37(s,1H),8.01(d,1H),7.77(d,1H),7.65(d,2H),7.39(t,2H),7.22–7.04(m,5H),6.78(dd,1H),5.65(br.s,2H),5.20–5.00(m,1H),4.99–4.70(m,2H),4.19–3.99(m,4H),3.80–3.64(m,2H),3.31–3.10(m,4H),3.10–2.93(m,4H),2.89–2.71(m,2H),2.66–2.55(m,1H),2.37(dd,1H),2.27–2.06(m,2H),2.04–1.93(m,1H).
LCMS m/z=778.3[M+1] +
Example 3:
5- (3- (4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -piperidin-1-yl) - [1,3 '-diazacyclobutane ] -1' -yl) -N- (2, 6-dioxopiperidin-3-yl) pyridinecarboxamide (Compound 3)
5-(3-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-[1,3'-biazetidin]-1'-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide
The first step is as follows: 5- (3-4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -piperidin-1-yl) - [1,3 '-diazetidine ] -1' -yl) -picolinic acid methyl ester (3b)
methyl 5-(3-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-[1,3'-biazetidin]-1'-yl)picolinate
1- (1- ([1,3' -diazacyclobut ] -3-yl) piperidin-4-yl) -3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] -pyrimidin-4-amine (3a) (synthesis method WO2020239103) (600mg,1.2mmol) was dissolved in 10mL of DMSO, 1.0mL of DIPEA and methyl 5-fluoropicolinate (200mg, 1.29mmol) were added, and the mixture was heated to 95 ℃ for 7H. The reaction mixture was cooled to room temperature, 100mL of purified water was added to precipitate a solid, which was filtered off, the filter cake was dissolved in a mixed solvent of dichloromethane/methanol (v/v) ═ 10:1, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give methyl 5- (3-4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -piperidin-1-yl) - [1,3 '-diazacyclobutane ] -1' -yl) -picolinate (3b) (500mg, yield: 66%).
LCMS m/z=632.3[M+1] +
The second step: 5- (3-4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) piperidin-1-yl) - [1,3 '-diazacyclobutane ] -1' -yl) -picolinic acid (3c)
5-(3-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-[1,3'-biazetidin]-1'-yl)picolinic acid
To methyl 5- (3-4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -piperidin-1-yl) - [1,3 '-diazetidine ] -1' -yl) -picolinate (3b) (500mg, 0.79mmol) was added a mixed solvent of 10mL of tetrahydrofuran, 10mL of methanol and 10mL of purified water, and sodium hydroxide solid (800mg,20mmol) was added and reacted at room temperature for 2H. The reaction solution was concentrated under reduced pressure, and the pH was adjusted to 6.0 with 1mol/L aqueous hydrochloric acid to precipitate a solid, which was then filtered to give a crude product of 5- (3-4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) piperidin-1-yl) - [1,3 '-diazacyclobutane ] -1' -yl) -picolinic acid (3c) (400 mg).
The third step: 5- (3- (4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -piperidin-1-yl) - [1,3 '-diazacyclobut ] -1' -yl) -N- (2, 6-dioxopiperidin-3-yl) pyridinecarboxamide (Compound 3)
5-(3-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-[1,3'-biazetidin]-1'-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide
To the crude 5- (3-4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) piperidin-1-yl) - [1,3 '-diazacyclobutyl ] -1' -yl) -picolinic acid (3c) (400mg) above was added 10mL of DMF followed by 3-aminopiperidine-2, 6-dione hydrochloride (250mg, 1.5mmol) and 1.0mL of triethylamine, followed by HATU (240mg, 0.63mmol), and reacted at room temperature for 16H. The reaction mixture was directly filtered by suction, and the filter cake was collected and washed with 20mL of ethyl acetate to give 5- (3- (4- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d ] pyrimidin-1-yl) -piperidin-1-yl) - [1,3 '-diazacyclobut ] -1' -yl) -N- (2, 6-dioxopiperidin-3-yl) pyridinecarboxamide (compound 3) (300mg, two-step total yield: 52% from compound 3 b).
1 H NMR(400MHz,DMSO-d 6 )δ10.81(br.s,1H),8.66(d,1H),8.23(s,1H),7.88–7.76(m,2H),7.70–7.62(m,2H),7.48–7.39(m,2H),7.23–7.08(m,5H),6.90(dd,1H),4.79–4.60(m,2H),4.05–3.94(m,2H),3.84–3.72(m,2H),3.71–3.60(m,1H),3.49–3.37(m,2H),3.09–2.94(m,3H),2.91–2.72(m,3H),2.58–2.51(m,1H),2.30–2.10(m,3H),2.10–1.95(m,3H),1.95–1.80(m,2H).
LCMS m/z=728.3[M+1] +
Biological test example
1. Cell proliferation inhibition assay
The Mino and SU-DHL-6 culture medium is RPMI1640+ 10% FBS, and is cultured at 37 deg.C and 5% CO 2 In an incubator. Cells were plated in 96-well plates. Wherein Mino and SUDHL-6 cells 5000 cells/well, 90. mu.L per well. Each well was dosed with 10 μ L of compound at different concentrations. Each concentration is provided with 3 multiple wells, the last column is DMSO solvent control group, at 37 deg.C and 5% CO 2 The culture was continued under the conditions for 72 hours. After 72 hours, 50. mu.L of detection reagent (Cell Viability Assay, Promega, G7573) was added to each well, mixed for 2 minutes, incubated at room temperature for 10 minutes, and the fluorescence signal value was measured using a microplate reader (PHERAstar FSX). The inhibition rate was calculated using formula (1), wherein V sample Reading for drug treatment group, V vehicle control Is the average of the solvent control group. Using origin9.2 software, the IC of a compound to inhibit cell proliferation was calculated 50 The value is obtained.
inhi.%=(1-V sample /V vehicle control ) X 100% of formula (1).
IC for inhibiting Mino cell proliferation by the compounds of the invention 50 The results are shown in Table 1-1.
TABLE 1-1 inhibition of Mino cell proliferation IC 50 Value of
Serial number | Compound number | IC 50 (nM) |
1 | Compound 1 | 136 |
2 | Compound 2 | 368 |
Compounds of the invention inhibit SU-DHL-6 IC of cell proliferation 50 The results are shown in tables 1-2.
TABLE 1-2 IC inhibition of SU-DHL-6 cells 50 Value of
Serial number | Compound numbering | IC 50 (nM) |
1 | Compound 2 | 219 |
2 | Compound 3 | 100 |
And (4) conclusion: the compound synthesized by the technology has certain inhibition effect on the proliferation of Mino cells (mantle cell lymphoma cells) and SU-DHL-6 cells (human B lymphoma cells).
Claims (10)
1. A compound of formula (I) or a stereoisomer, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, wherein
B-L-K (I);
L is selected from-Ak 1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak 5-;
ak1, Ak2, Ak3, Ak4 and Ak5 are each independently selected from CH 2 O or a bond;
cy1, Cy2, Cy3 and Cy4 are each independently selected from 3 to 12 membered heterocyclic ring, 3 to 12 membered cycloalkyl, 6 to 10 membered aryl or bond, said heterocyclic, cycloalkyl or aryl being optionally substituted with 1 to 4Selected from D, F, Cl, Br, I, OH, NH 2 、oxo、C 1 - 4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S, N;
R b1 、R b2 Or R b3 Each independently selected from H, D, F, Cl, Br, I, OH, NH 2 、CN、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said alkyl and alkoxy being optionally substituted with 1 to 4 substituents selected from D, F, Cl, Br, I, OH, NH 2 、CN、CONH 2 、C 1-4 Alkyl or C 1-4 Substituted by a substituent of alkoxy;
n1 is selected from 0, 1,2, 3,4 or 5;
n2 is selected from 0, 1,2, 3 or 4;
n3 is selected from 0, 1 or 2;
Q is each independently selected from the group consisting of a bond, -O-, -S-, -CH 2 -、-NR q -、-CO-、-NR q CO-、-CONR q -or 3-12 membered heterocycle, said heterocycle optionally substituted with 1 to 4 substituents selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1 - 4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S or N;
R q is selected from H or C 1-6 An alkyl group;
each F is independently selected from C 3-20 Carbocyclic ring, C 6-20 An aromatic ring, a 3-20 membered heterocyclic ring, or a 5-20 membered heteroaromatic ring, said heterocyclic or heteroaromatic ring containing 1 to 4 heteroatoms selected from O, S or N;
R k2 each independently selected from the group consisting of a bond, -C (═ O) -, -C (═ Se) -, -C (═ S) -, -P (═ O) H-, -P (═ O) (CH) 3 )-、-S(=O) 2 -, -S (═ O) -, or-C (R) k3 ) 2 -;
R k5 Is selected from C (R) k3 ) Or N;
R k1 or R k3 Each independently selected from H, D, F, Cl, Br, I, OH, O, NH 2 、CN、COOH、CONH 2 、C 1 - 6 Alkyl radical, C 1-6 Alkoxy radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl or 3-8 membered heterocyclyl, said alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl or heterocyclyl being optionally substituted with 1 to 4 substituents selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocyclyl containing 1 to 4 heteroatoms selected from O, S or N;
or two R k3 And together with the atom or ring skeleton to which they are directly attached form C 3-8 Carbocyclic or 3-8 membered heterocyclic ring, two R k1 And together with the atom or ring skeleton to which they are directly attached form C 3-8 A carbocycle or 3-8 membered heterocycle optionally substituted with 1 to 4 substituents selected from F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S or N;
R k4 each independently selected from H, D, OH, NH 2 、CN、CONH 2 、C 1-6 Alkyl radical, C 3-8 Cycloalkyl or 3-8 membered heterocyclyl, said alkyl, cycloalkyl or heterocyclyl being optionally substituted by 1 to 4 substituents selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocyclyl containing 1 to 4 heteroatoms selected from O, S or N;
p1 or p2 are each independently selected from 0, 1,2, 3,4 or 5.
2. A compound according to claim 1 or a stereoisomer, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, wherein
L is selected from-Cy 1-, -Cy1-Cy2-, -Cy1-Cy2-Cy3-, -Cy1-Cy2-Cy3-Cy4-, -Cy1-Ak2-, -Cy1-Ak2-Cy2-, -Cy1-Cy2-Ak 3-or-Cy 1-Cy2-Ak3-Cy 3-;
ak2 and Ak3 are respectively and independently selected from CH 2 Or O;
cy1, Cy2 or Cy3 are each independently selected from one of the following substituted or unsubstituted groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, azacyclohexenyl, piperidinyl, morpholinyl, piperazinyl, 1, 4-diazepinyl, phenyl, cyclopropylaminocyclopropyl, cyclopropylbenzocyclobutyl, cyclopropylpentacyclopentyl, cyclopropylaminocyclohexyl, cyclobutylbenzocyclobutyl, cyclobutylpentacyclopentyl, cyclobutylocyclocyclohexyl, cyclopentocyclocyclopentyl, cyclopentocyclocyclohexyl, cyclohexylocyclohexyl, cyclopropylspirocyclopropyl, cyclopropylspirocyclobutyl spirobutyl, cyclopropylspirocyclopentyl, cyclopropylspirocyclohexyl, cyclobutyl spirocyclobutyl spirobutyl, cyclobutylspirocyclopentyl, cyclobutyl spirocyclohexyl, cyclopentspirocyclohexyl, cyclohexylspirocyclohexyl, cyclopropyloazetidinyl, cyclopropylpyrrolopyrrolidinyl, cyclopropylnopiperidinyl, cyclobutyloazetidinyl, cyclobutylobutylkinyl, cyclopentylpiperidyl, cyclohexylspirocyclohexyl, cyclopropyloxazetidiyl, cyclopropyloxazetidinyl, cyclobutyloxazetidinyl, cyclopentapyridyl, cyclopropyloxazetidinyl, cyclobutyloxazetidinyl, piperidinyl, and cyclopentadienylyl, Cyclobutyl-pyrrolopyrrolidinyl, cyclobutyl-piperidyl, cyclopentoazetidinyl, cyclopentylpyrrolidinyl, cyclopentylpiperidinyl, cyclohexylazacyclobutyl, cyclohexylpyrrolopyrrolidinyl, cyclohexylaminopiperidinyl, azetidinyl-azetidinyl, azetidinylbopyrrolidinyl, azetidinylpiperidyl, pyrrolidinyloazetidiyl, pyrrolidinylpyrrolopyrrolidinyl, pyrrolidinylpiperidylpiperidyl, piperidinoazetidiyl, piperidinylpyrrolidinyl, piperidinopiperidinyl, cyclobutyl-spiroazetidinyl, cyclobutyl-spiropyrrolidinyl, cyclopentyl-spiroazetidinyl, cyclopentyl-spiropyrrolyl, cyclopentyl-spiropiperidinyl, cyclohexyl-spiroazetidinyl, cyclohexyl-spiropiperidinyl, azetidinyl-spiropyrrolyl, Azetidinyl spiropiperidinyl, pyrrolidinyl spiroazetidinyl, pyrrolidinyl spiropyrrolidineA group, pyrrolidinylspiropiperidinyl, piperidinyl spiroazetidinyl, piperidinyl spiropyrrolidinyl, piperidinyl spiropiperidinyl, When substituted, is optionally substituted with 1 to 2 substituents selected from D, F, Cl, Br, I, OH, NH 2 、COOH、CN、=O、C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 Substituted by a substituent of alkoxy;
R b1 、R b2 Or R b3 Each independently selected from H, D, F, Cl, Br, I, OH, NH 2 、CN、CONH 2 Methyl, ethyl, methoxy and ethoxy, wherein the methyl, ethyl, methoxy and ethoxy are optionally selected from 1 to 4 of D, F, Cl, Br, I, OH and NH 2 、CN、CONH 2 、C 1-4 Alkyl or C 1-4 Substituted with a substituent of alkoxy;
n1 or n2 are each independently selected from 0, 1,2 or 3.
3. The compound of claim 2, or a stereoisomer, deuteride, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, wherein,
each Q is independently selected from the group consisting of a bond, -O-, -S-, -CH 2 -、-NH-、-CO-、-NHCO-、-CONH-;
Each F is independently selected from C 3-7 Monocycloalkyl radical, C 5-10 And cycloalkyl group, C 5-12 Spiro cycloalkyl, C 5-10 Bridged cycloalkyl radical, C 4-7 Mono-heterocycloalkyl, C 5-10 And heterocyclic alkyl, C 5-12 Spiroheterocycloalkyl, C 5-10 Bridged heterocycloalkyl, C 6-14 Aryl, 5-10 membered heteroaryl, said heteroaryl or heterocycloalkyl containing 1 to 4 heteroatoms selected from O, S or N;
R k8 each independently selected from the group consisting of a bond,C(CH 3 ) 2 、CH 2 、-C(=O)-、-C(=Se)-、-C(=S)-、-P(=O)H-、-P(=O)(CH 3 )-、-S(=O) 2 -、-S(=O)-;
R k6 Each independently selected from S, O, CH 2 Or NH;
R k7 each is independently selected from CH or N;
R k9 each independently selected from O, S, CH 2 CH, NH, or N;
p3 is selected from 1,2 or 3;
R k2 each independently selected from-C (═ O) -, -C (═ Se) -, -C (═ S) -, -P (═ O) H-, -P (═ O) (CH) 3 )-、-S(=O) 2 -, -S (═ O) -, or-CH 2 -;
R k5 Selected from CH or N;
R k1 、R k3 each independently selected from H, D, F, Cl, Br, I, OH, O, NH 2 、CF 3 、CN、COOH、CONH 2 、C 1 - 4 Alkyl or C 1-4 Alkoxy, said alkyl or alkoxy being optionally substituted by 1 to 4 substituents selected from D, F, Cl, Br, I, OH or NH 2 Substituted with the substituent(s);
or two R k3 And together with the atom or ring skeleton to which they are directly attached form C 3-6 Carbocyclic or 3-7 membered heterocyclic ring, two R k1 And together with the atom or ring skeleton to which they are directly attached form C 3-6 A carbocycle or 3-7 membered heterocycle, optionally substituted with 1 to 4 groups selected from D, F, Cl, Br, I, OH, ═ O, NH 2 、CN、COOH、CONH 2 、C 1-4 Alkyl or C 1-4 Alkoxy, said heterocycle containing 1 to 4 heteroatoms selected from O, S or N;
R k4 each independently selected from H, D, OH, NH 2 、CF 3 CN or C 1-4 An alkyl group.
4. The compound of claim 3, or a stereoisomer, deuteride, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof,
each F is independently selected from Cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [1.1.1]Pentyl alkyl, bicyclo [2.2.2 ] s]Octyl, adamantane, phenyl, naphthyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, furanyl, thienyl, thiazolyl, 2-pyridone, benzoxazolyl, pyridoimidazolyl, benzimidazolyl, benzopyrrolidineOxazolyl, benzothiazolyl, benzothienyl, benzofuranyl, benzopyrolyl, benzopyridyl, benzopyrazinyl, benzopyrimidinyl, benzopyrazinyl, benzotriazinyl, pyrrolopyrrolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridazinyl, pyrrolopyrazinyl, imidazopyrimidinyl, imidazopyridinyl, imidazopyrazinyl, imidazopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, pyrazolopyridinyl, pyrimidopyridinyl, pyrimidopyridazinyl, pyrimidopyrimidinyl, pyridopyridinyl, pyridopyrazinyl, pyridopyridazinyl, pyridazinopyridazinyl, pyridazinopyrazinyl, pyrazinopyrazinyl;
each Q is independently selected from a bond or-CH 2 -;
R k2 Each independently selected from-C (═ O) -, -C (═ Se) -, -C (═ S) -, -P (═ O) H-, -P (═ O) (CH) 3 )-;
R k1 、R k3 Each independently selected from H, D, F, Cl, Br, I, OH, O, NH 2 、CF 3 、CN、COOH、CONH 2 Methyl, ethyl, methoxy, ethoxy, said methyl, ethyl, methoxy, ethoxy optionally being substituted by 1 to 4 groups selected from D, F, Cl, Br, I, OH or NH 2 Substituted with the substituent(s);
or two R k1 And the atom or ring skeleton to which they are directly attached together form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl group, said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl group being optionally substituted by 1 to 4 substituents selected from D, F, Cl, Br, I, OH or NH 2 Substituted with the substituent(s);
R k4 each independently selected from H or methyl.
5. The compound of claim 4, or a stereoisomer, deutero-compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, wherein,
l is selected from-Cy 1-Cy2-Cy 3-or-Cy 1-Cy2-Ak3-Cy 3-;
ak3 is selected from CH 2 ;
6. The compound of claim 5, or a stereoisomer, deutero-compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, wherein,
L is selected from one of the structural fragments shown in Table L-1;
k is selected from one of the structural fragments shown in Table K-1.
7. The compound of claim 1, or a stereoisomer, a deuteride, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof, wherein the compound is selected from one of the structures shown in table S-1.
8. A pharmaceutical composition comprising a compound of any one of claims 1-7, or a stereoisomer, tautomer, deuteron, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or co-crystal thereof, and a pharmaceutically acceptable carrier.
9. Use of a compound according to any one of claims 1-8, or a stereoisomer, a tautomer, a deutero-solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof, for the preparation of a medicament for the treatment of a disease associated with the inhibition or degradation of BTK kinase.
10. The use according to claim 9, wherein the disease is selected from cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021107626355 | 2021-07-15 | ||
CN202110762635 | 2021-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114920746A true CN114920746A (en) | 2022-08-19 |
Family
ID=82807313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210485930.5A Pending CN114920746A (en) | 2021-07-15 | 2022-05-16 | BTK (BTK inhibitory or degrading agent) and application thereof in medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114920746A (en) |
-
2022
- 2022-05-16 CN CN202210485930.5A patent/CN114920746A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7373992B2 (en) | Substituted pyrazole compounds and methods of their use for the treatment of hyperproliferative diseases | |
CN115667238B (en) | Five-membered ring derivative and application thereof in medicine | |
CN114437035A (en) | Compound for inhibiting and degrading IRAK4, pharmaceutical composition and pharmaceutical application thereof | |
CA3023261A1 (en) | Modulators of the integrated stress pathway | |
CA2884355C (en) | Imidazolin-5-one derivative useful as fasn inhobitors for the treatment of cancer | |
KR20100038108A (en) | Triazine kinase inhibitors | |
CN114763352A (en) | GLP-1 receptor agonist and application thereof in medicine | |
CN112778284B (en) | Pyrimido-cyclic derivative and application thereof in medicine | |
CN114507235A (en) | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | |
CN113292536A (en) | Compound capable of degrading Bcr-Abl or PARP and preparation method and pharmaceutical application thereof | |
CN116375742A (en) | Azaaromatic ring derivative, composition and pharmaceutical application thereof | |
CN117425646A (en) | Phosphono derivative, composition thereof and pharmaceutical application thereof | |
CN116529248A (en) | Benzene ring derivative, composition and pharmaceutical application thereof | |
CN113999233A (en) | BTK inhibitor ring derivative, preparation method and pharmaceutical application thereof | |
CN117897385A (en) | Compound for degrading Bcl-2 family proteins and application of compound in medicine | |
CN118206558A (en) | Compound capable of inhibiting and degrading AuroraA, pharmaceutical composition and pharmaceutical application thereof | |
CA3160606A1 (en) | Pd-l1 antagonist compound | |
KR20240132059A (en) | Compounds that inhibit and degrade IRAK4, pharmaceutical compositions thereof and applications in pharmacy | |
CN116496318A (en) | Heterocyclic derivative, composition and pharmaceutical application thereof | |
CN114920746A (en) | BTK (BTK inhibitory or degrading agent) and application thereof in medicine | |
CN115340552A (en) | Heterocyclic derivative and application thereof in medicine | |
CN114075168A (en) | Pyrazole derivative and application thereof in medicine | |
CN118255780A (en) | Compound for inhibiting and degrading c-MYC and medical application thereof | |
CN115919859B (en) | Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine | |
CN117229263A (en) | Compound for inhibiting or degrading Bcl6 and application of compound in medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231227 Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region Applicant after: Tibet Haisike Pharmaceutical Co.,Ltd. Address before: 611130 No.136 Baili Road, Wenjiang cross strait science and Technology Park, Chengdu, Sichuan Applicant before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |